aod9604 clinical trial AOD-9604 Research Peptide AOD-9604 | Peptide Report

Following these results, a prospective first-in-human imaging phase I study (NCT03665155) was conducted to assess [ 89 Zr]Zr-DFO-daratumumab uptake in MM patients using PET/CT

M., Nofziger, C., Dossena, S., Paulmichl, M

It features a C20 fatty diacid moiety that binds to albumin, protecting the peptide from enzymatic degradation and extending its half-life to approximately 6 days

Diagnosis can be rather complex as the symptoms can take years for it to surface

It is also shown to have positive impacts on a vast range of problems including fatigue and migraines

5-Amino-1MQ is the lead potent, selective small-molecule inhibitor of NNMT identified to date